| 前收盘价格 | 319.06 |
| 收盘价格 | 307.48 |
| 成交量 | 560,364 |
| 平均成交量 (3个月) | 256,166 |
| 市值 | 34,172,278,784 |
| 市盈率 (P/E TTM) | 605.51 |
| 预期市盈率 (P/E Forward) | 39.37 |
| 价格/销量 (P/S) | 7.18 |
| 股市价格/股市净资产 (P/B) | 8.60 |
| 52周波幅 | |
| 利润日期 | 6 Nov 2025 |
| 营业毛利率 | -9.40% |
| 营业利益率 (TTM) | 0.99% |
| 稀释每股收益 (EPS TTM) | -3.69 |
| 季度收入增长率 (YOY) | 48.60% |
| 总债务/股东权益 (D/E MRQ) | 28.49% |
| 流动比率 (MRQ) | 1.96 |
| 营业现金流 (OCF TTM) | 212.02 M |
| 杠杆自由现金流 (LFCF TTM) | -120.68 M |
| 资产报酬率 (ROA TTM) | -3.22% |
| 股东权益报酬率 (ROE TTM) | -11.44% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | BeOne Medicines Ltd. | 看涨 | - |
AIStockmoo 评分
0.5
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | 1.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.50 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne’s revenue. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Growth |
| 内部持股比例 | 17.31% |
| 机构持股比例 | 43.94% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Capital International, Inc./Ca/ | 30 Sep 2025 | 325,844 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 408.00 (RBC Capital, 32.12%) | 购买 |
| 中 | 398.00 (28.88%) | |
| 低 | 383.00 (Morgan Stanley, 24.02%) | 购买 |
| 平均值 | 396.17 (28.29%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 335.91 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Truist Securities | 24 Nov 2025 | 400.00 (29.53%) | 购买 | 332.71 |
| RBC Capital | 18 Nov 2025 | 408.00 (32.12%) | 购买 | 363.92 |
| 07 Nov 2025 | 395.00 (27.91%) | 购买 | 319.97 | |
| Citigroup | 10 Nov 2025 | 405.00 (31.15%) | 购买 | 329.20 |
| Citizens | 07 Nov 2025 | 396.00 (28.23%) | 购买 | 319.97 |
| Morgan Stanley | 20 Oct 2025 | 383.00 (24.02%) | 购买 | 318.59 |
| JP Morgan | 08 Oct 2025 | 385.00 (24.67%) | 购买 | 351.09 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合